Jia wei zhi pu san
Food supplement declared in France, declaration No 2020-4-1114
Jia wei zhi pu san, from Calebasse, is a food supplement declared in France. Status: withdrawn from the market on 19 March 2024. Main ingredients: Acorus calamus 0.75 g per day, Ginkgo biloba 0.75 g per day, Polygala tenuifolia 0.75 g per day, Wolfiporia cocos 0.75 g per day. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- Calebasse
- Status
- Withdrawn from the market on 19 March 2024
- Form
- Capsule
- Daily dose
- 3 g
- Not recommended (according to the manufacturer)
- Children (under 12), Pregnant women, Infants (under 1 year), Taking anticoagulants
- Objectives stated by the manufacturer (these are not authorised claims)
- Memory, Concentration
Declaration 301784, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Acorus calamus L. | Rhizome | Extrait sec aqueux | 0.75 g |
| Ginkgo biloba L. | Feuille | Extrait sec aqueux | 0.75 g |
| Polygala tenuifolia Willd. | Rhizome | Extrait sec aqueux | 0.75 g |
| Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb. | Sclérote | Extrait sec aqueux | 0.75 g |
Additives
E1204
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Consultez votre médecin ou votre pharmacien en cas d’usage concomitant d’anticoagulants.
Regulatory points
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Information
Withdrawn from the market on 19 March 2024, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ginkgo biloba L.
Read the warning, when it applies and the studies cited
GINKGO - GINKGO BILOBA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Sources cited by Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Sources cited by Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Jia wei zhi pu san Calebasse, declared in 2020, withdrawn from the market : different composition: 0 ingredient(s) added, 1 missing
- Jia wei zhi pu san Calebasse, declared in 2020, withdrawn from the market : different composition: 0 ingredient(s) added, 1 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Jia wei zhi pu san: composition and regulation”, https://compoatlas.com/en/supplements/products/301784-jia-wei-zhi-pu-san, updated 15 November 2026.